Last 36 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 6.90 | 0.41 | — | — | — | — | — | — | — | — | — | — | — | — | 91.62 | — | — | — | 21.17 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +332.8% | — | — | — | — | — | — | |
| P/S Ratio | 1.64 | 0.32 | 16.83 | 56.83 | 6.44 | 23.29 | 4.46 | 8.32 | 0.84 | 7.41 | 7.27 | 8.88 | 11.08 | 14.93 | 2.23 | 7.77 | 13.23 | 13.15 | 2.63 | 11.95 | 30.07 |
| — | -98.6% | +277.3% | +583.1% | +665.4% | +214.5% | -38.7% | -6.4% | -92.4% | -50.4% | +225.7% | +14.3% | -16.2% | +13.5% | -15.0% | -35.0% | -56.0% | +393.4% | -95.8% | -87.7% | -51.2% | |
| P/B Ratio | 8.64 | 1.77 | — | 22.90 | 5.24 | 5.26 | 1.97 | 1.29 | 1.44 | 3.82 | 2.92 | 3.16 | 5.02 | 3.35 | 2.56 | 2.81 | 3.56 | 3.09 | 2.91 | 4.37 | 5.60 |
| — | -66.5% | — | +1672.3% | +264.1% | +37.7% | -32.3% | -59.1% | -71.3% | +14.2% | +13.9% | +12.3% | +40.9% | +8.4% | -12.0% | -35.7% | -36.4% | -46.7% | -67.7% | -37.7% | +25.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.18 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 6.51 | 0.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 16.40 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 18.80 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.1% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 85.6% | 85.1% | -408.6% | 17.9% | -213.5% | -277.4% | -225.5% | 31.7% | -116.7% | -277.2% |
| — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +16.8% | +17.5% | +124.5% | +460.1% | +140.1% | +130.7% | -81.2% | -43.7% | -82.9% | -0.1% | -395.2% | +105.0% | +88.5% | +66.0% | |
| Operating Margin | -692.8% | 76.0% | -734.7% | -2382.3% | -634.4% | -1153.6% | -433.6% | -1216.5% | -13.4% | -315.7% | -302.4% | -275.0% | -312.4% | -555.3% | -6.4% | -302.8% | -383.9% | -321.5% | 11.9% | -180.3% | -398.2% |
| — | +106.6% | -69.5% | -95.8% | -4646.6% | -265.4% | -43.4% | -342.3% | +95.7% | +43.1% | -4636.0% | +9.2% | +18.6% | -72.7% | -153.8% | -68.0% | +3.6% | -564.2% | +101.4% | +85.9% | +63.4% | |
| Net Margin | -679.2% | 76.5% | -692.5% | -2192.2% | -597.5% | -1063.4% | -387.7% | -1101.6% | -3.8% | -275.2% | -256.4% | -227.0% | -272.8% | -488.3% | 2.4% | -277.1% | -363.1% | -310.7% | 12.4% | -182.3% | -397.4% |
| — | +107.2% | -78.6% | -99.0% | -15526.6% | -286.4% | -51.2% | -385.2% | +98.6% | +43.6% | -10583.3% | +18.1% | +24.9% | -57.1% | -80.2% | -52.0% | +8.6% | -547.7% | +101.5% | +85.6% | +63.0% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -181.6% | 233.8% | -11160.2% | -111.8% | -84.4% | -53.8% | -36.8% | -36.6% | -1.7% | -31.3% | -23.5% | -23.0% | -27.9% | -24.8% | 0.7% | -23.1% | -22.4% | -17.0% | 3.6% | -15.7% | -17.5% |
| — | +534.6% | -30207.2% | -205.7% | -4897.1% | -71.7% | -56.8% | -58.6% | +94.0% | -26.4% | -3338.3% | +0.1% | -24.5% | -45.5% | -79.6% | -46.9% | -28.4% | -135.0% | +113.3% | +25.5% | +3.3% | |
| ROA | -37.5% | 67.6% | -10.4% | -8.6% | -11.9% | -10.0% | -8.0% | -9.2% | -0.4% | -7.8% | -6.4% | -5.7% | -6.4% | -6.4% | 0.2% | -6.0% | -6.5% | -5.3% | 1.1% | -5.0% | -6.7% |
| — | +774.4% | -30.1% | +6.8% | -2714.1% | -29.0% | -24.5% | -60.9% | +93.4% | -20.6% | -3498.4% | +3.9% | +0.8% | -20.5% | -82.4% | -18.4% | +3.2% | -126.4% | +108.1% | +55.1% | +34.9% | |
| ROIC | -159.2% | 743.9% | — | — | -294.3% | -66.4% | -31.3% | -28.7% | -4.3% | -28.4% | -24.2% | -27.0% | -35.7% | -36.7% | -4.0% | -56.5% | -38.4% | -26.0% | 66.7% | — | — |
| — | +1220.6% | — | — | -6740.6% | -133.5% | -29.5% | -6.0% | +87.9% | +22.6% | -507.6% | +52.1% | +6.9% | -41.1% | -106.0% | — | — | — | +321.8% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.18 | 0.18 | — | 3.33 | 1.18 | 0.66 | 0.55 | 0.43 | 0.34 | 0.29 | 0.24 | 0.21 | 0.29 | 0.25 | 0.21 | 0.23 | 0.20 | 0.18 | 0.16 | 0.17 | 0.16 |
| — | -72.5% | — | +667.0% | +252.6% | +125.3% | +131.3% | +106.7% | +15.6% | +17.7% | +15.0% | -8.9% | +43.6% | +40.9% | +32.1% | +32.3% | +27.6% | +21.3% | -41.3% | -21.4% | -17.4% | |
| Debt / EBITDA | — | 0.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.19 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.83 | 4.10 | 5.26 | 5.25 | 3.83 | 3.76 | 3.78 | 3.34 | 3.40 | 3.29 | 3.52 | 3.53 | 3.18 | 3.95 | 4.90 | 6.91 | 7.74 | 4.82 | 5.54 | 6.24 | 5.37 |
| — | +9.3% | +39.0% | +57.2% | +12.9% | +14.1% | +7.5% | -5.3% | +6.8% | -16.5% | -28.2% | -49.0% | -58.9% | -18.1% | -11.5% | +10.8% | +44.1% | -18.8% | +25.0% | +6.6% | -13.2% | |
| Quick Ratio | 3.83 | 4.10 | 5.26 | 5.25 | 3.83 | 3.76 | 3.78 | 3.34 | 3.40 | 3.29 | 3.52 | 3.53 | 3.18 | 3.95 | 4.90 | 6.91 | 7.74 | 4.82 | 5.54 | 6.24 | 5.37 |
| — | +9.3% | +39.0% | +57.2% | +12.9% | +14.1% | +7.5% | -5.3% | +6.8% | -16.5% | -28.2% | -49.0% | -58.9% | -18.1% | -11.5% | +10.8% | +44.1% | -18.8% | +25.0% | +6.6% | -13.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 36 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALEC stock.
Alector, Inc.'s current P/E is 6.9x. The average P/E over the last 1 quarters is 0.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Alector, Inc.'s current operating margin is -692.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Alector, Inc.'s business trajectory between earnings reports.